148 related articles for article (PubMed ID: 7955564)
1. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
[TBL] [Abstract][Full Text] [Related]
2. Immunological response in chronic hepatitis C virus infection during interferon alpha therapy.
Panasiuk A; Prokopowicz D; Zak J
Hepatogastroenterology; 2004; 51(58):1088-92. PubMed ID: 15239252
[TBL] [Abstract][Full Text] [Related]
3. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity.
Nielsen B; Hokland M; Justesen J; Hasselbalch H; Ellegaard J; Hokland P
Eur J Haematol; 1989 Jan; 42(1):50-9. PubMed ID: 2914594
[TBL] [Abstract][Full Text] [Related]
4. Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.
Pawlotsky JM; Hovanessian AG; Roudot-Thoraval F; Robert N; Bouvier M; Babany G; Duval J; Dhumeaux D
Antimicrob Agents Chemother; 1996 Feb; 40(2):320-4. PubMed ID: 8834873
[TBL] [Abstract][Full Text] [Related]
5. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
6. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection.
Pár G; Rukavina D; Podack ER; Horányi M; Szekeres-Barthó J; Hegedüs G; Paál M; Szereday L; Mózsik G; Pár A
J Hepatol; 2002 Oct; 37(4):514-22. PubMed ID: 12217606
[TBL] [Abstract][Full Text] [Related]
7. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
[TBL] [Abstract][Full Text] [Related]
8. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
9. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
10. Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C.
Malaponte G; Passero E; Leonardi S; Monte V; Lauria C; Mazzarino C; Sciotto A; Russo Mancuso G; Di Gregorio F; Musumeci S
Acta Haematol; 1997; 98(2):83-8. PubMed ID: 9286304
[TBL] [Abstract][Full Text] [Related]
11. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
12. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
[TBL] [Abstract][Full Text] [Related]
13. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell function and malignant cell phenotype in hairy cell leukaemia.
Ogmundsdóttir HM; Thorsteinsson L; Sigfússon A; Sveinsdóttir S; Björnsson S; Eyjólfsson G; Jóhannesson GM; Jensson O
APMIS; 1992 Jan; 100(1):10-20. PubMed ID: 1536717
[TBL] [Abstract][Full Text] [Related]
15. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
[TBL] [Abstract][Full Text] [Related]
16. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia.
Villamor N; Reverter JC; Montserrat E; Urbano-Ispízua A; Vives-Corrons JL; Rozman C
Leukemia; 1992 Jun; 6(6):547-52. PubMed ID: 1376376
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
Millar BC; Bell JB; Powles RL
Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
[TBL] [Abstract][Full Text] [Related]
18. 2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.
Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
Gastroenterol Jpn; 1991 Oct; 26(5):603-10. PubMed ID: 1752391
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass.
Bianchi A; Omedé P; Attisano C; Camponi A; Dianzani U; Boccadoro M; Pileri A; Massaia M
Haematologica; 1991; 76(5):383-8. PubMed ID: 1806441
[TBL] [Abstract][Full Text] [Related]
20. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]